GNLKQ (Genelink) Operating Margin %: -204.41% (As of Sep. 2013)


What is Genelink Operating Margin %?

Genelink GNLKQ Operating Margin % is -204.41% as of Sep. 2013.

Operating Margin % is calculated as Operating Income divided by its Revenue. Genelink's Operating Income for the three months ended in Sep. 2013 was $-0.60 Mil. Genelink's Revenue for the three months ended in Sep. 2013 was $0.30 Mil. Therefore, Genelink's Operating Margin % for the quarter that ended in Sep. 2013 was -204.41%.

The historical rank and industry rank for Genelink's Operating Margin % or its related term are showing as below:


GNLKQ's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -86.83
* Ranked among companies with meaningful Operating Margin % only.

Genelink's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Genelink's Operating Income for the three months ended in Sep. 2013 was $-0.60 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2013 was $-2.16 Mil.


Genelink  (OTCPK:GNLKQ) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Genelink Operating Margin % Related Terms


Genelink Operating Margin % Historical Data

* Premium members only.

The historical data trend for Genelink's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genelink Operating Margin % Chart

Genelink Annual Data
Trend Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -35.02 -28.76 -30.65 -76.14 -159.32

Genelink Quarterly Data
Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -209.88 -232.28 -89.25 -38.59 -204.41

GNLKQ vs VITIF, HSTC, NTRR: Operating Margin % Comparison

For the Biotechnology subindustry, Genelink's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genelink Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genelink's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Genelink's Operating Margin % falls into.



Genelink Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Genelink's Operating Margin % for the fiscal year that ended in Dec. 2012 is calculated as

Operating Margin %=Operating Income (A: Dec. 2012 ) / Revenue (A: Dec. 2012 )
=-3.403 / 2.136
=-159.32 %

Genelink's Operating Margin % for the quarter that ended in Sep. 2013 is calculated as

Operating Margin %=Operating Income (Q: Sep. 2013 ) / Revenue (Q: Sep. 2013 )
=-0.603 / 0.295
=-204.41 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -204.41% mean?
Genelink (GNLKQ) has a Operating Margin % of -204.41% as of Sep. 2013. Operating margin is the ratio of total operating income to net sales. View historical data on Genelink and its competitors.
Is Genelink's Operating Margin % too high?
Genelink's current Operating Margin % is -204.41%.
How does Genelink's Operating Margin % compare to VITIF and HSTC?
Genelink's Operating Margin % of -204.41% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Genelink and its competitors. Genelink's current Operating Margin % is -204.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genelink stock overvalued right now?
Genelink (GNLKQ) has a current Operating Margin % of -204.41%. The current Operating Margin % is -204.41%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Genelink (GNLKQ), the current Operating Margin % is -204.41% as of Sep. 2013. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genelink Business Description

Address 8250 Exchange Drive, Suite 120, Orlando, FL, USA, 32809
Genelink Inc is a genetics-based, personal healthcare firm that has developed DNA assessments measuring personal DNA tendencies. These small differences in DNA, called SNPs can indicate genetic variants, the protein products of which may not be performing at optimal levels and can be linked to aging and other wellness issues. The company's scientists use the DNA assessments information from each client to formulate products to optimize health and wellness within normal ranges. The company has a compilation of issued and pending patents that center on using DNA analysis for the purpose of customizing nutrition and skin care formulations for wellness and anti-aging.